Over recent years, the rising popularity of therapeutic peptides and proteins has signaled an important and necessary shift in focus on behalf of the healthcare industry toward more innovative, targeted interventions. The need for cost-effective solutions in response to the long lead times and high costs of conventional drug manufacturing has prompted major developments in synthetic peptide research and development. Attracted to the ease of manufacturing, pharmaceutical companies are increasingly developing peptide-based products ranging from novel drug candidates to clinical diagnostic tools. As growing investment and funding fuel innovations in the industry, the global peptide therapeutics market is poised for a breakthrough.
Current State of the Global Peptide Therapeutics Market
Currently, peptide therapeutics constitute an emerging market within the more established sphere of biologic agents. The overall success of peptide therapeutics can be attributed to their range of clinical benefits and outperformance of many conventional pharmacologic interventions. With high target specificity, low toxicity, and favorable safety profiles, these products have garnered increasing adoption and awareness among both the scientific and medical industries. Due to the lower instance of molecular interaction and relative ease of metabolism into component amino acid residues, peptide therapeutics present lower toxicity levels which can be especially beneficial for patients requiring long-term treatment.
Last year, the global peptide therapeutics market was valued at $32.1 billion with forecasts anticipating rapid upward movement. According to a market report from Mordor Intelligence, the sector is expected to witness a revenue of $51.36 billion in 2026, rising at a compound annual growth rate of 9.66% over the course of the next 5 years.
North America has been and is projected to continue dominating the overall global market due to high levels of awareness of peptide therapeutic pathways, increasing necessity for diagnostics in cancer and other chronic diseases, as well as a booming biotechnology industry. Although, the peptide therapeutics market in the Asia-Pacific region is experiencing the fastest pace of growth largely spurred by Takeda Pharmaceutical and Zealand Pharma’s significant licensing agreements and advancements in drug discovery.
Factors Spurring Market Growth
Currently, the increasing prevalence of cancers and metabolic disorders among the global population alongside heightened healthcare expenditure and a growing aging population are some of the key factors influencing market expansion. Surging investment in research and development of peptide-based products as well as an increasing number of approved therapeutics contribute to these upward trends across the globe.
Rising rates of cancer worldwide are forecasted to boost activity in this market as peptide treatments offer favorable prospects for targeted drug delivery in cancer patients. At the same time, the continuously increasing prevalence of chronic diseases – which continue to be the leading cause of death and disability across the global population – accelerates the need for the development of safe, effective therapeutic interventions.
Technological advancements are a critical component of the market’s success and will further propel growth in the industry as drug discovery, development, and delivery are optimized. The adoption of hybrid technologies to scale production will also bolster market growth.
Lastly, heightened awareness and adoption of peptide therapeutics among clinicians and their patients is expected to fuel expansion in the sector over the forthcoming years as these products continue to offer effective treatment outcomes associated with fewer adverse effects than certain conventional pharmaceutics.
Future Expansion Opportunities
According to Research and Markets estimates, the global peptide therapeutic market is projected to exceed $60 billion by the year 2026 driven primarily by a strong clinical pipeline and favorable commercialization parameters. There is promising potential within the market for expansion due to the safety, targeted delivery, and high specificity of peptide therapeutics, particularly in the case of chronic diseases and illnesses requiring prolonged treatment. Furthermore, novel drug development and product launches geared toward the treatment of chronic metabolic disorders are set to provide significant opportunities for market growth.
The global peptide therapeutics market has been surging over recent years and is expected to continue growing exponentially through this decade spurred by technological advancements, increased adoption, and population needs.
In an effort to better equip clinicians with the tools and education needed to become leaders in this rapidly growing market, IPS offers a Membership program providing unparalleled access to the latest news, exclusive resources, and knowledge in peptide therapeutics. Join fellow experts in peptide therapeutics by becoming a member today.